Report : North America Blood Collection Tubes for Liquid Biopsy Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (ccfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, Intracellular RNA Tubes, and Others), Material (Glass and Plastic), Application (In-Vitro Diagnostics (IVD) and Research), and End User (Genetic Diagnostic Labs, R&D Centres, Conventional Diagnostic Centres, and Others)
The plastic segment by material is estimated to lead the market growth during the forecast period.
According to a new market research study of “North America Blood Collection Tubes for Liquid Biopsy Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product Type, Application, End User and Country.” The North America blood collection tubes for liquid biopsy market is expected to reach US$ 11.81 thousand by 2028 from US$ 35.80 thousand in 2021; it is estimated to grow at a CAGR of 18.6% from 2021-2028. The report highlights trends prevailing in the North America blood collection tubes for liquid biopsy market and the factors driving market along with those that act as hindrances.
Health systems globally are witnessing a substantial increase in the prevalence of cancer. According to the World Health Organization, cancer is the second-leading cause of mortality worldwide. According to the International Agency for Research on Cancer (IARC), the global cancer burden has increased to 19.3 million cases and 9.96 million cancer deaths by 2020. According to the data published by the World Health Organization (WHO), in 2019, around 9.6 million deaths were caused by cancer globally. Moreover, according to the same data, prostate, lung, colorectal, liver, and stomach cancer are most observed in men, while breast, colorectal, and cervical cancer are the most common among women.
Furthermore, according to a study published by the National Cancer Institute, in 2021, the incidence of cancer in the US likely reached 1.9 million. In addition, around 0.6 million people were anticipated to die in 2021 in the US due to cancer.
Liquid biopsies are used for diagnosing non–small cell lung cancer (NSCLC) and screening or as a companion diagnostic for other types of cancers such as colorectal, breast, gastrointestinal, prostate, and ovarian. Early prognosis, reduced cost, therapy monitoring, acquired drug resistance, detection of tumor heterogeneity, and patient comfort are benefits of liquid biopsy over traditional cancer diagnostics approaches (by eliminating the need for surgery). As a result, the preference for liquid biopsy increases parallelly with the rise in cancer prevalence. As a result, blood collection tubes for liquid biopsy contribute to the organization's strategy to detect cancer early and precisely, allowing for quick treatment and enhancing cancer patients' survival rates, thereby boosting the growth of the North America blood collection tubes for liquid biopsy market. The factors mentioned above boost the growth of the North America blood collection tubes for liquid biopsy market.
The North America had been adversely affected by the COVID-19 pandemic like other regions. However, recent spikes in cases and hospitalizations suggest that pressure will become more widespread in the coming months, with less resiliency across the country to support surges in care demand. To manage demand early in the pandemic, some clinicians relied on resources from other parts of the country, such as supplies, and postponed "elective" care to free up resources for COVID-19 patients. The region of the Americas has now surpassed 100 million cases of COVID-19, latest Pan American Health Organization (PAHO) epidemiological data show, with the US driving a 36% increase in cases in North America in the second week of December and parts of Central and South America reporting declines.
The COVID-19 pandemic negatively impacted the people suffering from cancer and cancer surveillance capacities. Reduced resources and availability to care as a result of the pandemic made cancer detection and treatment more difficult, resulting in lower incidence, higher mortality, and lower survival in the future. People with active cancer are more susceptible to infectious pathogens due to compromised immune systems caused by cancer or its treatment, including surgery and chemotherapy. This raised fears that COVID-19 problems and mortality may be more common in cancer patients.
The North America blood collection tubes for liquid biopsy market, based on product, has been classified into ccfDNA tubes, cfRNA tubes, CTC tubes, gDNA tubes, intracellular RNA tubes, and others. The North America blood collection tubes for liquid biopsy market, based on material, is segmented into glass and plastic. The North America blood collection tubes for liquid biopsy market, based on application, is segmented into In-vitro diagnostics (ivd), and research. Geographically, the North America blood collection tubes for liquid biopsy market is sub-segmented into Brazil, Argentina and Rest of SCAM.
PreAnalytiX GmbH, Biocept, Inc., F. HOFFMANN-LA ROCHE LTD., STRECK, Norgen Biotek Corp, Exact Sciences Corporation, Greiner AG, Apostle Sciences, MagBio Genomics, Inc and Zymo Research Corporation are among the leading companies operating in the North America blood collection tubes for liquid biopsy market.
Contact Person: Sameer Joshi
Email Id: email@example.com